Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5496 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 6 7 8 ... 53 54 55  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Atriva Therapeutics–Meneldor: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Atriva Therapeutics–SEVERAL: investment, 201901 financing round Series A first closing led by Meneldor + HTGF 2019-01-03
Takeda–Rentschler: biologics contract manufacturing, 201901– supply service continued production for Shire in acquired manufacturing site in Milford 2019-01-03
CARB-X–Germany (govt): grant, 201901–202212 BMBF commits €40m over 4 years 2019-01-01
Curetis–Vienna (govt): grant, 201901–202106 co-funding of developm project of Ares Genetics for AMR assay by Vienna Business Agency 2019-01-01
Marinomed–EU (govt): credit, 20901–2027 up to €15m EIB credit 2019–2022 repayable 2024–2027 2019-01-01
Blink Biomedical–Valneva: investment, 201812 existing shareholding of 43.3% by Valneva consolidated via equity method 2018-12-31
Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply FIA-MRMS system 2018-12-31
Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply twelve impact-II UHR-QTOF LC-MS/MS systems 2018-12-31
Murdoch Univ–Bruker: mass spectrometer, 2018–201909 supply two timsTOF Pro LC/CCS/MS/MS systems 2018-12-31
Murdoch Univ–Bruker: NMR spectrometer, 2018–201909 supply seven Avance IVDr 600 NMR systems 2018-12-31
Harpoon Therapeutics–SEVERAL: investment, 201812–201902 IPO $76m at $14/share 2018-12-27
Nabriva–Hercules Technology: credit, 201812–202306 term loan up to $75m with $25m up front von Hercules Capital 2018-12-21
Evitria–Afinum: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
Evitria–SHS: investment, 201812 acquisition majority stake by Afinum Achte Beteiligungs GmbH & Co KG + SHS V Medtech Investments GmbH 2018-12-20
France (govt)–Novartis: investment, 201812– proposed acquisition of CellforCure from LFB by Novartis 2018-12-20
AC Immune–WuXi Pharmatech: biologics contract manfucturing, 201812– collab strategic alliance biologics CDMO with WuXi Biologics 2018-12-19
Annexon Biosciences–Novartis: investment, 201812 financing round Series C totalling $75m incl exisiting + co-investor NVF 2018-12-19
Annexon Biosciences–SEVERAL: investment, 201812 financing round Series C $75m led by new investor Bain Capital Life Sciences 2018-12-19
Cellestia Biotech–PPF Group: investment, 201812 financing round Series A totalling CHF20m incl existing + co-lead investor Sotio/PPF Group 2018-12-19
Cellestia Biotech–SEVERAL: investment, 201812 financing round Series A CHF20m from FC Capital + Sotio/PPF Group + ETP Ventures + private investors 2018-12-19
Amgen–Molecular Partners: cancer immunotherapy, 201812– collab $50m upfront + $497m milestones + royalties ww excl developm + commerc rights to MP0310 2018-12-18
Novartis–Curetis: antibiotics research, 201812– collab Sandoz to use Ares Genetics’ antibiotic resistance database ARESdb 2018-12-18
PreOmics–High-Tech Gründerfonds: investment, 201812 financing round Series A totalling €3.3m incl HTGF + Think.Health Ventures + business angels 2018-12-18
PreOmics–SEVERAL: investment, 201812 financing round Series A €3.3m from HTGF + Think.Health Ventures + business angels 2018-12-18
PreOmics–Think.Health Ventures: investment, 201812 financing round Series A totalling €3.3m incl HTGF + Think.Health Ventures + business angels 2018-12-18
Seer–Invus Group: investment, –201812 financing rounds Series A + B totalling $36m incl Series B lead investor Invus 2018-12-17
Seer–Maverick Ventures: investment, –201812 financing rounds Series A + B totalling $36m incl Series A lead investor Maverick Ventures 2018-12-17
Seer–SEVERAL: investment, –201812 financing rounds Series A + B of $36m until 12/18 as company emerges from stealth 2018-12-17
Shire–Rentschler: investment, 201812–201901 acquisition €na of Shire’s manufacturing facility in Milford, MA by Rentschler Biopharma SE 2018-12-17
Orchard Therapeutics–Sirion Biotech: gene therapy manufacturing technology, 201812– license for stem cell gene therapies 2018-12-14
Lonza–ERS Genomics: CRISPR technology, 201812– license €na for bioproduction products + services + iPSC research to Lonza Pharma & Biotech 2018-12-13
Mestrelab Research–Bruker: investment, 201812 acquisition of majority share €na by Bruker incl strateg collab + partnership 2018-12-13
AC Immune–Lilly: credit, 201812 convertible note $50m in connection with license + collab agreement 2018-12-12
Imprint Analytics–SGS: credit, 201812– convertible loan as part of strategic partnership 2018-12-12
Lilly–AC Immune: tau aggregation inhibitors, 201812– collab + license agreem CHF80m upfront + CHF1.76b milestones + royalties 2018-12-12
Santhera–SEVERAL: investment, 201812 capital increase CHF23.5m with 3.134m shares at CHF7.5/share 2018-12-12
SGS–Imprint Analytics: food analysis, 201812– collab strategic partnership isotope analysis for proof of origin + authenticity food testing 2018-12-12
DenovoMatrix–High-Tech Gründerfonds: investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
DenovoMatrix–Saxony (govt): investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
DenovoMatrix–SEVERAL: investment, 201812 seed financing round from HTGF + TGFS 2018-12-11
Chiesi–Centogene: genetic services, 201812– collab epidemiology study in lysosomal storage diseases with focus on AM by Centogene for Chiesi GmbH 2018-12-10
genOway–Merck (DE): CRISPR technology, 201812– collab strategic alliance €na incl ww excl license to produce + sell genome-edited rodent models 2018-12-10
genOway–Merck (DE): CRISPR technology, 202001– collab strategic alliance extention incl adding non-excl license for all non-rodent animal cell models 2018-12-10
Lonza–General Electric: biologics manufacuturing technology, 201812–2020 supply biologics facility in Guangzhou using KUBio platform by GE Healthcare 2018-12-10
Alacris–Seedmatch: financial services, 201812– crowdfunding campaign up to €800k via Seedmatch platform 2018-12-06
Alacris–SEVERAL: investment, 201812– crowdfunding campaign up to €800k via Seedmatch platform 2018-12-06
Hookipa–Valneva: drug development services, 201812–202111 collab + manufacturing agreem for developm of immunotherapies with Valneva Sweden AB 2018-12-06
Merck (DE)–Cyclica: drug discovery services, 201812– collab using cloud-based proteome screening platform for small molecule drug development 2018-12-06
Novartis–Qiagen: molecular companion diagnostics, 201812– collab developm of CDx for alpelisib (BYL719) 2018-12-06
AC Immune–Hopp Group: investment, 201812 existent investment dievini Hopp owns 27% of AC Immune SA 2018-12-05
Apogenix–Hopp Group: investment, 201812 existent investment dievini Hopp owns 92% of Apogenix AG 2018-12-05
Cassiopea–Hopp Group: investment, 201812 existent investment dievini Hopp owns 1% of Cassiopea SpA 2018-12-05
Cosmo Pharmaceuticals–Hopp Group: investment, 201812 existent investment dievini Hopp owns 5% of Cosmo SpA 2018-12-05
CureVac–Hopp Group: investment, 201812 existent investment dievini Hopp owns 80% of CureVac AG 2018-12-05
Heidelberg Pharma–Hopp Group: investment, 201812 existent investment dievini Hopp owns 83% of Heidelberg Pharma AG 2018-12-05
Immatics–Hopp Group: investment, 201812 existent investment dievini Hopp owns 38% of Immatics GmbH 2018-12-05
Joimax–Hopp Group: investment, 201812 existent investment dievini Hopp owns 85% of Joimax GmbH 2018-12-05
Molecular Health–Hopp Group: investment, 201812 existent investment dievini Hopp owns 95% of Molecular Health GmbH 2018-12-05
Novaliq–Hopp Group: investment, 201812 existent investment dievini Hopp owns 93% of Novaliq GmbH 2018-12-05
Anagenesis–Alsace (govt): investment, 201812 financing round Series A 1st closing totalling €3m incl existing investor Cap Innov’Est 2018-12-04
Anagenesis–Boehringer: investment, 201812 financing round Series A 1st closing totalling €3m incl new investor BIVF 2018-12-04
Anagenesis–SEVERAL: investment, 201812 financing round Series A €3m 1st closing from BIVF + Cap Innov’Est 2018-12-04
Boehringer–Domain Therapeutics: drug discovery services, 201812– collab + license agreem €na discovery of GPCR-targeting CNS drugs 2018-12-04
Leo Pharma–Evotec: drug discovery services, 201812– collab €na integrated drug discovery to generate leads against innovative dermatic targets 2018-12-04
Argenx–JnJ: investment, 201812 investment $200m of 1.767m new shares at €100.02/share representing 4.68% shareholding by JJDC 2018-12-03
JnJ–Argenx: cusatuzumab, 201812– collab + license agreem ww with Cilag GmbH for up to $1.6b incl $300m upfront cash 2018-12-03
Resistell–SEVERAL: investment, 201812 seed financing round CHF850k 2018-12-01
Dispendix–Cellink: investment, 201811 acquisition €5m of Dispendix GmbH by Cellink AB 2018-11-30
Hookipa–DarwinHealth: personalised medicine, 201811– collab research + license agreem to develop I-O treatments using systems biology 2018-11-28
Jecure Therapeutics–Roche: investment, 201811 acquisition of Jecure by Genentech from Versant Ventures 2018-11-27
Spindiag–SEVERAL: investment, 201811 financing round Series A €3m 2018-11-27
X4 Pharmaceuticals–Arsanis: investment, 201811– reverse merger with former X4 owners to hold 70% + Arsanis to be renamed X4 ANNOUNCED 2018-11-27
Adrenomed–HBM: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor HBM Healthcare Investments 2018-11-26
Adrenomed–MC Services: public relations, 201811 service existent by MC Services 2018-11-26
Adrenomed–SEVERAL: investment, 201811 financing round Series D €24m with new + co-lead investors Wellington + HBM plus existing investors 2018-11-26
Adrenomed–Wellington Partners: investment, 201811 financing round Series D totalling €24m incl new + co-lead investor Wellington Partners 2018-11-26
Bayer–Cyclica: drug discovery services, 201811– collab using cloud-based proteome screening platform for small molecule drug development 2018-11-26
Suntory–BRAIN: food ingredients, 201811– collab €na developm natural beverage solutions with SBFE 2018-11-26
F2G Ltd–EU (govt): credit, 201811– InnovFin €24m loan from EIB to F2G Biotech GmbH for antifungals r+d 2018-11-22
Evotec–Immuneering: drug discovery software, 201811– collab AI-driven small-molecule drug discovery for hereditary metabolic diseases 2018-11-21
Quarton International–Cowen: investment, 201811–201901 acquisition of Quarton by Cowen 2018-11-20
Inflazome–Forbion: investment, 201811 financing round Series B totalling €40m incl new + lead investor Forbion Capital Partners 2018-11-19
Inflazome–Fountain Healthcare Partners: investment, 201811 financing round Series B totalling €40m incl existing + co-investor FHP 2018-11-19
Inflazome–Longitude Capital: investment, 201811 financing round Series B totalling €40m incl new + co-investor Longitude Capital 2018-11-19
Inflazome–Novartis: investment, 201811 financing round Series B totalling €40m incl existing + co-investor Novartis Venture Fund 2018-11-19
Inflazome–SEVERAL: investment, 201811 financing round Series B €40m from Forbion + Longitude Capital + NVF + Fountain Healthcare Partners 2018-11-19
Lonza–Chaim Sheba Medical Center: cell therapy manufacturing technology, 201811 collab existent to evaluate + test Cocoon technology 2018-11-19
Roche–Immunocore: ImmTAC technology, 201811– collab expansion co-developm of IMC-C103C with $100m upfront/near-term with Genentech 2018-11-19
Noxxon–SEVERAL: investment, 201811 capital increase €6.21m incl €4.4m from Acuitas Capital LLC 2018-11-16
Boehringer–Epizyme: small-molecule cancer drugs, 201811– collab strategic ww to develop inhibitors toward two epigenetic targets 2018-11-15
Cadent Therapeutics–Access Industries: investment, 201811 financing round Series B totalling $40m incl co-investor Access Industries 2018-11-15
Cadent Therapeutics–Atlas Venture: investment, 201811 financing round Series B totalling $40m incl co-lead investor Atlas Venture 2018-11-15
Cadent Therapeutics–Clal Industries: investment, 201811 financing round Series B totalling $40m incl co-investor Clal Biotechnology Industries 2018-11-15
Cadent Therapeutics–Cowen: investment, 201811 financing round Series B totalling $40m incl co-lead investor Cowen Healthcare Investments 2018-11-15
Cadent Therapeutics–Novartis: investment, 201811 financing round Series B totalling $40m incl co-investor Novartis Institutes for Biomedical Research 2018-11-15
Cadent Therapeutics–Qiming: investment, 201811 financing round Series B totalling $40m incl co-investor Qiming Venture Partners 2018-11-15
Cadent Therapeutics–SEVERAL: investment, 201811 financing round Series B $40m co-led by Cowen Healthcare Investments + Atlas Venture 2018-11-15
I-Mab–MorphoSys: antibody cancer drug, 201811– license excl Greater China + KR for MOR210 with $3.5m upfront + $101.5m milestones + royalties 2018-11-15
Alicona–Bruker: investment, 201811–201812 acquisition €na of Alicona Imaging GmbH by Bruker 2018-11-14
next pagenext page 1 2 3 ... 6 7 8 ... 53 54 55  next pagenext page



Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 650x65px

» top